课题基金 / 基金详情

Identification of GPR52 antagonists as potential treatments for Huntington Disease

Identification of GPR52 antagonists as potential treatments for Huntington Disease
鉴定 GPR52 拮抗剂作为亨廷顿病的潜在治疗方法
批准号:
9205646
负责人:
Marc Ferrer
金额:
$1.9万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Marc Ferrer的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
3D Bioprinted Omentum tissue to model ovarian cancer metastasis
3D Bioprinted retina models for drug screening
3D Bioprinted lung cancer models for drug screening
国内基金
海外基金
新型GPR52小分子抑制剂的设计合成
孤儿G蛋白偶联受体GPR52负向别构调控剂设计和机制研究
  • 批准号:
    22107072
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    吴屹然
  • 依托单位:
特异抑制G蛋白偶联受体GPR52的全合成人源化纳米抗体的鉴定及验证
  • 批准号:
    32070939
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    丁澦
  • 依托单位:
靶向GPR52对亨廷顿病潜在治疗作用的研究
  • 批准号:
    81870990
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2018
  • 负责人:
    鲁伯埙
  • 依托单位: